Fundraising Fox
/Companies
Sign in

IconOVir Bio

New York, US · Founded 2018 · Delaware corporation · 8 employees on LinkedIn · 4 known investors

Find your way into IconOVir Bio

Sign up to see every warm intro you have to IconOVir Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the IconOVir Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.

BiotechHealthtech

Founders & leadership

SASean Algeo
Sean AlgeoVP Finance - Controller & Treasurer
MAMark A. McCamish
Mark A. McCamishPresident and CEO
DMDavid M. Tanen
David M. TanenNamed on SEC filingAdvisor at Vida Ventures

Board

DCDavid Chang
David ChangBoard directorScientific Advisor at Vida Ventures
HKHelen Kim
Helen KimBoard directorSenior Managing Director at Vida Ventures
JLJakob Loven
Jakob LovenBoard Member2021–2024Partner at Nextech Invest
JKJoshua Kazam
Joshua KazamBoard directorCo-Founder and Director at Vida Ventures
ASArie S. Belldegrun
Arie S. BelldegrunBoard directorFounder and Senior Managing Director at Vida Ventures

Investors · 4

Nextech Investlisted by Nextech InvestZurich · $648K – $3.2M

How we know: Nextech Invest's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Wellington Managementlisted by Wellington ManagementBoston · $5M – $50M

How we know: funding news · Not right? Tell us

Vida VenturesreportedLos Angelesvia Arie Belldegrun · board

How we know: board seat on SEC Form D · funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$97.2M disclosed across 2 rounds · 2020–2023

▶$20.2MraisedJun 2024 · 34 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sean AlgeoExecutive Officer, Promoter
  • Nicole van de LeuvExecutive Officer
  • Helen KimDirector
  • Heba NowyhedExecutive Officer
  • David ChangDirector, Promoter
  • William KaelinDirector
  • Jakob LovenDirector
  • Joshua KazamDirector, Promoter
  • Julie MaltzmanExecutive Officer
  • Mark A. McCamishExecutive Officer, Director
  • John HuynhExecutive Officer
  • David M. TanenExecutive Officer, Promoter
Offering amount
$20.2M
Amount sold
$20.2M
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$77MraisedDec 2020 · 47 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David ChangDirector, Promoter
  • Helen KimDirector
  • Sean AlgeoExecutive Officer, Promoter
  • Jakob LovenDirector
  • Mark A. McCamishExecutive Officer, Director
  • Joshua A. KazamDirector
  • David M. TanenExecutive Officer, Promoter
  • Arie S. BelldegrunDirector, Promoter
Offering amount
$77M
Amount sold
$77M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through IconOVir Bio went on to found or lead other companies.

Arie BelldegrunDirector, PromoterFounded Kite PharmaJoshua KazamDirectorFounded Allogene Therapeutics

Related companies · 1

VirVir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities. The company targets patients with unmet medical needs across these therapeutic areas.

Companies working in the same space as IconOVir Bio.

In the news

IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors - IconOViriconovir.com · Jan 2021

Frequently asked questions

What does IconOVir Bio do?
Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.
Who are IconOVir Bio's investors?
IconOVir Bio's investors include GV (Google Ventures), Nextech Invest, Wellington Management, Vida Ventures.
How much funding has IconOVir Bio raised?
IconOVir Bio has disclosed $97.2M raised across 2 rounds.
Where is IconOVir Bio headquartered?
IconOVir Bio is headquartered in New York, US.